Guizhou Sanli
Guizhou Sanli operates an integrated traditional-Chinese-medicine pharmaceutical business spanning herb cultivation through marketing, developing, making, and selling the drugs.
- Public company
- Anshun, Guizhou, CNChina
Guizhou Sanli operates an integrated traditional-Chinese-medicine pharmaceutical business spanning herb cultivation through marketing, developing, making, and selling the drugs.
Guizhou Sanli Pharmaceutical Co., Ltd reports a **9.3% drop in nine-month revenue** to **CNY 972.52 million** (vs. CNY 1,038.5 million year-over-year) for the period ending **September 30, 2026**. The company’s sales figures match its reported revenue, reflecting a contraction in performance compared to the same period in 2025. No further operational details or segment-specific breakdowns are disclosed in the earnings update.
Oct 2026MarketScreenerNews article
Guizhou Sanli Pharmaceutical Co., Ltd declares an annual dividend of **CNY 0.34 per share**, payable to shareholders on **June 26, 2025**. The ex-dividend date is also set for June 26, 2025, with the record date on June 25, 2025. This follows the company’s standard practice of distributing profits to investors.
Apr 2025MarketScreenerNews article
Guizhou Sanli Pharmaceutical Co., Ltd reports first-quarter 2025 revenue of **CNY 408.59 million**, a decline from **CNY 422.02 million** in the same period of 2024. The company’s sales figures match its reported revenue for the quarter ended March 31, 2025. The earnings release highlights a sequential drop in financial performance year-over-year.
Apr 2025MarketScreenerNews article
Guizhou Sanli Pharmaceutical Co., Ltd reports **CNY 2.14 billion in sales and revenue** for the full year ended December 31, 2024. This marks a significant increase from the prior year’s figures of **CNY 1.63 billion** in both sales and revenue. The company’s financial performance reflects growth in its pharmaceutical operations over the reported period.
Apr 2025MarketScreenerNews article